BioTech 365

APRIL 27, 2021

Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington’s Disease Therapeutics Conference Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to … Continue reading →

In-Vivo 40

In-Vivo Antibody 40

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

BioTech 365

SEPTEMBER 15, 2020

In vivo efficacy on a par with gold standard deruxtecan-based ADCs Poster to be presented at World ADC meeting on 17 September 2020 AMSTERDAM–(BUSINESS WIRE)–Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, based on proprietary … Continue reading →

In-Vivo 40

In-Vivo Antibody Drugs 40

XTalks

DECEMBER 13, 2024

Blenrep is an antibody-drug conjugate (ADC) created by linking a B-cell maturation antigen (BCMA)-targeting monoclonal antibody to a potent cytotoxic agent, auristatin F, using a stable, non-cleavable linker technology. The therapy is also under review in other major markets globally. Patients were randomized to BVd or DVd regimens.

Antibody 99

Antibody In-Vivo Trials In-Vitro 99

The Pharma Data

JUNE 17, 2022

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The two antibodies also were fully active against Alpha, Beta, Gamma, and Delta variants. 2 subtypes.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Pharmaceutical Technology

MARCH 9, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

pharmaphorum

JULY 22, 2021

Celltrion’s COVID-19 therapeutic, CT-P59, is a monoclonal antibody (mAb) with activity against COVID-19. It was identified as a potential treatment through the screening of antibody candidates from recovered patients and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. Overcoming obstacles.

Antibody 105

Antibody Clinical Trials Clinical Trials Trials 105

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

Pharmaceutical Technology

MAY 24, 2023

Morphogenesis is targeting a newly identified delta receptor on myeloid-derived suppressor cells (MDSCs) using its new bi-functional antibody-drug conjugates (ADCs) class. It is building many MDSC-targeted, bi-functional ADCs for in vitro and in vivo characterisation, with lead selection expected by the end of next year.

Gene Therapy 130

Gene Therapy In-Vivo In-Vitro Immune Response 130

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

pharmaphorum

JANUARY 13, 2021

The Series B fundraiser follows the FDA’s decision to grant Breakthrough Therapy designation last month for a combination of its lead immune-oncology therapies IO102 and IO103, with anti-PD-1 monoclonal antibodies for patients with metastatic melanoma.

Vaccination 95

Vaccination Vaccine Development In-Vivo 95

XTalks

APRIL 22, 2022

Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

pharmaphorum

JULY 13, 2022

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment. dosing of *first patient* with VERVE-101, an in vivo CRISPR base editing medicine. Today: we are announcing.

Gene Editing 98

Gene Editing Trials Drugs In-Vivo 98

pharmaphorum

APRIL 25, 2022

The UNC and NCSU team, led by biomedical engineer Yevgeny Brudno, report in Nature Biotechnology how they have developed an implant that can generate the CAR-T cells in vivo. In some cases where the cancer is particularly aggressive, that timeframe may simply be too long to be a viable option for the patient.

Engineer 105

Engineer In-Vivo FDA Approval Manufacturing 105

Scienmag

FEBRUARY 22, 2021

Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. ” But how do these antibodies function within the tumor? Using innovative in vivo imaging approaches, scientists […]. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.”

In-Vivo 41

In-Vivo Antibody Scientist Allergies 41

Pharmaceutical Technology

SEPTEMBER 10, 2008

IS: Our genotoxicity testing includes the core battery of the tests requested by EMEA/ICH including mutagenicity in vitro, chromosomal aberration test in vitro and micronucleus test in vivo. Natalie Coomber: Can you provide a quick background on the history of Biotest and the main work it is currently undertaking?

In-Vitro 100

In-Vitro Genotoxicity In-Vivo Development 100

The Pharma Data

OCTOBER 29, 2020

The first presentation of new data characterizing the anti-ChemR23 antibody was at the FOCIS Virtual Annual Meeting held October 28-31, 2020. The data presented show that OSE-230 is the first monoclonal antibody triggering the activation of specialized receptors of resolution to restor e tissue homeostasis, integrity and function s.

Antibody 40

Antibody In-Vivo Development Clinical Trials 40

BioTech 365

SEPTEMBER 2, 2020

SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc.

DNA 40

DNA In-Vivo Protein Gene 40

XTalks

AUGUST 17, 2020

This typically involves taking T cells from the body, engineering chimeric receptor antigens (CAR) and inserting them into the cells, expanding the cells ex vivo and injecting them back into the body. Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

APRIL 12, 2021

C4XD said it has developed a molecule small enough to be formulated into a pill, which has also been able to block IL-17 in vivo. Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal worth up to €414 million ($492 million).

Drugs 52

Drugs In-Vivo Licensing Licensing 52

WCG Clinical

MAY 28, 2024

The currently approved CD-19 CAR products are autologous, ex vivo cellular therapies. Recent headlines have highlighted the potential for Chimeric Antigen Receptor (CAR)-based therapies to provide clinical benefits to persons affected by lupus. In these cases B cell depletion is a feature, not a bug.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

pharmaphorum

APRIL 29, 2021

To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. A Meeting Point for the Field’s Experts. About Hanson Wade.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

The Pharma Data

MARCH 25, 2022

Researchers at Karolinska Institutet in Sweden have developed a novel strategy for identifying potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants. The approach led to the discovery of multiple nanobodies that in cell cultures and mice effectively blocked infection with different SARS-CoV-2 variants.

In-Vivo 52

In-Vivo Antibody Research Vaccination 52

pharmaphorum

JANUARY 17, 2023

Conjugation of targeting ligands such as GalNAc, transferrin receptor antibodies, and lipophilic moieties to siRNAs and ASO have facilitated delivery to liver, muscle, and CNS tissues, respectively, in preclinical or clinical studies. In addition, the construction of a specialised manufacturing facility for mRNA vaccines was agreed.

Vaccination 97

Vaccination Vaccine In-Vivo In-Vitro 97

The Pharma Data

JANUARY 12, 2021

Nielsen of Vivo Capital and Vanessa Malier of Kurma Partners will join IO Biotech’s board of directors as part of the closing of the financing. COPENHAGEN, Denmark , Jan. Additionally, Dr. Priyanka Belawat of HBM Partners, Jack B. On December 15, 2020 , the U.S. ” “HBM is excited to be joining IO Biotech as a shareholder.

In-Vivo 40

In-Vivo Antibody Vaccination Vaccine 40

The Pharma Data

DECEMBER 21, 2020

Acticor is developing glenzocimab (ACT017), a humanized Antibody Fragment (Fab). Evidence of antithrombotic efficacy of glenzocimab and safety of inhibition of GPVI have been established both ex vivo and in vivo. 22, 2020 10:14 UTC. GARDEN will enroll 60 patients in France and in Brazil. The Professor Victor A. link] product.

In-Vivo 40

In-Vivo Production Antibody Development 40

Roots Analysis

SEPTEMBER 13, 2023

Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Development 40

Development Antibody Protein Drug Delivery Systems 40

Roots Analysis

DECEMBER 8, 2021

Biopreservation is the exclusive biological approach designated for the preservation of cells, tissues and organs ex-vivo for the purpose of storage, shipment and transportation. Biopreservation media is one of the most crucial entity in conferring effectiveness. F) to 8°C (46.4°F).

In-Vivo 52

In-Vivo Packaging Packaging Biobanking 52

Delveinsight

FEBRUARY 11, 2021

Immune-stimulating antibodies, which target the receptor CD40, are emerging as promising therapies for pancreatic cancer. Immune-stimulating antibodies, which target the receptor CD40, are emerging as promising therapies for pancreatic cancer. Enhancing the response to immuno-oncology in pancreatic cancer.

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

The Pharma Data

APRIL 22, 2023

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. “It’s harder and takes longer to produce a T-cell-based vaccine than an antibody-based one,” said Kirimanjeswara.

Vaccination 40

Vaccination Vaccine Protein Antibody 40

Pharma Marketing Network

JANUARY 20, 2021

Perhaps this omission is because the systemically administered vaccines are unable to stimulate robust immune responses in the mucosae, despite generating systemic neutralizing antibody (and possibly T cell) responses.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

Roots Analysis

AUGUST 8, 2023

Ligand-targeted Liposomes: These liposomes can be employed for site- specific targeting by attaching ligands (including antibodies, peptides, and carbohydrates) to their surface or to the terminal end of the attached PEG chains. Bangham, in 1961 at the Babraham Institute, University of Cambridge.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs In-Vivo 52

The Pharma Data

DECEMBER 11, 2020

of the University of Michigan in Ann Arbor, and colleagues found that a single dose of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B (HB), provides effective transduction in HB patients, including patients who have antibody titers as high as 678. In one study, Haydar Frangoul, M.D., Abstract No.

Gene Editing 52

Gene Editing Gene Gene Therapy In-Vivo 52

The Pharma Data

NOVEMBER 29, 2020

Observed CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim results. The interim immunogenicity analysis also included CMV-neutralizing antibody data assessed from 33 individuals, a subset of the 41 included in the efficacy analysis. NEW YORK and VIENNA, Austria, Nov.

Vaccine 40

Vaccine Vaccination Clinical Trials Clinical Trials 40

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

The Pharma Data

APRIL 22, 2023

These backpacks are loaded with anti-inflammatory molecules that direct the carrier cells’ differentiation into anti-inflammatory cells in vivo. The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 million individuals that currently have to live with the disease.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40